Similar articles

• Benefits of Targeted Use of 5α-Reductase Inhibitors in Patients With Prostate Cancer-Reply.

  Sarkar RR, Rose BS. Sarkar RR, et al. JAMA Intern Med. 2019 Oct 1;179(10):1442. doi: 10.1001/jamainternmed.2019.3890. JAMA Intern Med. 2019. PMID: 31589266 No abstract available.
• Reduced Risk of Prostate Cancer With 5α-Reductase Inhibitors.

  Thompson I Jr, Goodman P, Tangen C. Thompson I Jr, et al. J Natl Cancer Inst. 2018 Nov 1;110(11):1159-1160. doi: 10.1093/jnci/djy038. J Natl Cancer Inst. 2018. PMID: 29547919 Free PMC article. No abstract available.
• Re: Association of Treatment with 5α-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer.

  Taneja SS. Taneja SS. J Urol. 2019 Nov;202(5):844. doi: 10.1097/01.JU.0000580116.14376.dc. Epub 2019 Oct 9. J Urol. 2019. PMID: 31403925 No abstract available.
• The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.

  Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. Marks LS, et al. J Urol. 2006 Sep;176(3):868-74. doi: 10.1016/j.juro.2006.04.024. J Urol. 2006. PMID: 16890642 Review.
• Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.

  van Leeuwen PJ, Kölble K, Huland H, Hambrock T, Barentsz J, Schröder FH. van Leeuwen PJ, et al. Eur Urol. 2011 Feb;59(2):183-90. doi: 10.1016/j.eururo.2010.09.035. Epub 2010 Dec 4. Eur Urol. 2011. PMID: 21130560 Review.